You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Adult Relapsed/Refractory ALL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

T-lymphoblastic Lymphoma, T-ALL Trial in Shanghai (CAR-T)

Recruiting
  • T-lymphoblastic Lymphoma
  • T-ALL
  • CAR-T
  • Shanghai, China
    Shanghai Ruijin Hospital
Nov 14, 2023

B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • HY004
  • +2 more
  • (no location specified)
Aug 18, 2023

Patients Who Received Inotuzumab Ozogamicin for B-cell ALL That

Not yet recruiting
  • Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
  • Inotuzumab Ozogamicin
  • (no location specified)
Nov 3, 2022

Acute Lymphoblastic Leukemia Trial (inotuzumab ozogamicin)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • inotuzumab ozogamicin
  • (no location specified)
Jan 6, 2023

CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL Trial in Suzhou (Treatment)

Recruiting
  • CAR
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 27, 2022

ALL, Adult, AML, Adult Trial (BN104)

Not yet recruiting
  • ALL, Adult
  • AML, Adult
  • (no location specified)
Sep 19, 2023

Leukemia, Lymphoblastic, Leukemia Trial in Houston (CB-103, Venetoclax)

Not yet recruiting
  • Leukemia, Lymphoblastic
  • Leukemia
  • Houston, Texas
    MD Anderson Cancer Center
Jul 19, 2022

Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CD19 specific Chimeric Antigen Receptor T Cell
  • Columbus, Ohio
    Nationwide Children's Hospital
Mar 9, 2023

ALL, Recurrent, Adult Trial in Frankfurt (Main), Kiel (Blinatumomab, Venetoclax)

Recruiting
  • ALL, Recurrent, Adult
  • Frankfurt (Main), Hessen, Germany
  • +1 more
Jan 6, 2022

T-ALL, Lymphoma, T-Cell Trial in Wuhan (SENL101)

Recruiting
  • T-ALL
  • Lymphoma, T-Cell
  • SENL101
  • Wuhan, Hubei, China
    Tongji Hospital
May 29, 2022

B-cell Acute Lymphoblastic Leukemia Trial (Tisagenlecleucel)

Withdrawn
  • B-cell Acute Lymphoblastic Leukemia
  • Tisagenlecleucel
  • (no location specified)
Feb 3, 2022

Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL Trial in Houston

Recruiting
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • +4 more
  • CD19.CAR-aNKT cells
  • +2 more
  • Houston, Texas
  • +1 more
Aug 19, 2022

Leukemia, Acute, AML, Adult, ALL, Adult Trial in Charlottesville (Palliative Care Visits)

Recruiting
  • Leukemia, Acute
  • +3 more
  • Palliative Care Visits
  • Charlottesville, Virginia
    University of Virginia
Apr 28, 2022

Leukemia, Acute Lymphocytic Trial in Durham (Copanlisib)

Recruiting
  • Leukemia, Acute Lymphocytic
  • Durham, North Carolina
    Duke Cancer Center
Jun 28, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL Trial in Memphis (biological,

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +2 more
  • CD19-CAR(Mem) T-cells
  • +5 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Aug 5, 2022

Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +2 more
  • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
  • Calgary, Alberta, Canada
  • +5 more
Jul 18, 2022

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
  • +4 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Sep 22, 2022

Acute Lymphoblastic Leukemia Trial in Bergamo, Monza (PTG-CARCIK-CD19)

Recruiting
  • Acute Lymphoblastic Leukemia
  • PTG-CARCIK-CD19
  • Bergamo, Italy
  • +1 more
Feb 12, 2022

Relapsed/Refractory Philadelphia Positive B-precursor ALL Trial in Worldwide (Blinatumomab)

Completed
Has Results
  • Relapsed/Refractory Philadelphia Positive B-precursor ALL
  • Duarte, California
  • +21 more
Sep 8, 2022

Acute Lymphoblastic Leukemia, in Relapse Trial in Bergamo, Monza (CARCIK-CD19)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • CARCIK-CD19
  • Bergamo, BG, Italy
  • +1 more
Feb 3, 2022

Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Wuhan (pCAR-19B cells)

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Refractory Acute Lymphoblastic Leukemia
  • pCAR-19B cells
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
May 12, 2021

B-cell Acute Lymphoblastic Leukemia Trial in New York (Tisagenlecleucel)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Tisagenlecleucel
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 13, 2022

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

Not yet recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Beijing, China
  • +3 more
Jul 20, 2023

Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute Trial in Japan, United States (DSP-5336)

Recruiting
  • Leukemia, Myeloid, Acute
  • Leukemia, Lymphocytic, Acute
  • Houston, Texas
  • +5 more
May 31, 2022